A
ArriVent BioPharma, Inc. (AVBP)
NGM – Real vaqt narxi. Valyuta: USD
21.43
-0.38 (-1.72%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
21.43
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
Aksiya tahlili uchun eng kuchli vositalarga ega bo'ling
NGM – Real vaqt narxi. Valyuta: USD
21.43
-0.38 (-1.72%)
Yopilishda: Mar 27, 2026, 4:00 PM EDT
21.43
0.00 (0.00%)
Bozordan keyin: Mar 27, 2026, 4:34 PM EDT
ArriVent BioPharma, Inc., klinik tadqiqotlar bosqichidagi biofarmatsevtika kompaniyasi, saraton kasalliklari bilan og'rigan bemorlarning qondirilmagan tibbiy ehtiyojlari uchun dori vositalarini aniqlash, ishlab chiqish va tijoratlashtirish bilan shug'ullanadi. Kompaniyaning asosiy ishlab chiqish nomzodi firmoneratinib bo'lib, u tirozin kinaz inhibitori bo'lib, u kichik hujayrali bo'lmagan o'pka saratoni (NSCLC) ning turli xil epidermis o'sish omili retseptorlari (EGFRm) mutatsiyalarida bir nechta klinik sinovlarda baholanmoqda, shu jumladan ilg'or yoki metastatik EGFRm NSCLC bemorlarini davolash uchun III bosqichli klinik sinov, ekson 20 qo'shimchalari mutatsiyalari bilan, shuningdek, faollashtiruvchi EGFRm NSCLC bemorlarini davolash uchun I b bosqichli klinik sinovlar, shu jumladan P-loop va alfa-c-helix siqish (PACC) mutatsiyalari va klassik EGFRm NSCLC bemorlari. Shuningdek, u oshqozon-ichak saratonini davolash uchun antikor-dorivor konjugati (ADC) bo'lgan ARR-217; va qattiq o'smalar uchun ARR-002, ARR-421 va ARR-173ni ishlab chiqmoqda. Kompaniya Aarvik Therapeutics Inc., Shanghai Allist Pharmaceuticals Co., Ltd., Beijing InnoCare Pharma Tech Co., Ltd., Jiangsu Alphamab Biopharmaceuticals Co., Ltd. va Lepu Biopharma Co. Ltd. bilan strategik hamkorlikka ega. ArriVent BioPharma, Inc. 2021 yilda tashkil etilgan va Pensilvaniya shtatining Nyu-taun-Skver shahrida joylashgan.
| Ism | Lavozim |
|---|---|
| Dr. James Paul Kastenmayer J.D., Ph.D. | General Counsel & Secretary |
| Dr. Stuart Lutzker M.D., Ph.D. | Co-Founder, President of Research & Development and Director |
| Dr. Zhengbin Yao Ph.D. | Co-Founder, Chairman, President & CEO |
| Mr. Brent S. Rice | Chief Commercial Officer |
| Mr. Winston Kung M.B.A. | CFO & Treasurer |
| Ms. Robin LaChapelle M.A. | Co-Founder & COO |
| Ms. Yang Wang Ph.D. | Chief Technology Officer |
| Sana | Turi | Hujjat |
|---|---|---|
| 2026-03-17 | 8-K | avbp-20260317x8k.htm |
| 2026-03-05 | S-8 | tm267878d1_s8.htm |
| 2025-11-10 | 10-Q | avbp-20250930x10q.htm |
| 2025-09-09 | 8-K | avbp-20250909x8k.htm |
| 2025-08-11 | 8-K | avbp-20250811x8k.htm |
| 2025-07-21 | 8-K | tm2521271d1_8k.htm |
| 2025-07-02 | 8-K | tm2519401d3_8k.htm |
| 2025-06-23 | 8-K | tm2518615d1_8k.htm |
| 2025-06-20 | 8-K | tm2518556d1_8k.htm |
| 2025-05-12 | 10-Q | avbp-20250331x10q.htm |